Research advance of brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis and treatment of pediatric cardiovascular diseases
WANG Ye-Feng, HUANG Xi-Yong
Department of Cardiology, Hunan Children's Hospital, Changsha 410007, China. huangiy@163.com
Abstract:Brain natriuretic peptide (BNP) and N-terminal brain natriuretic peptide (NT-proBNP) are important biomarkers for pediatric cardiovascular diseases. Peptide levels are associated with age and gender. Current studies have shown that BNP and NT-proBNP are valuable in the diagnosis of heart failure, with a high specificity and sensitivity. They also contribute to differentiating heart failure from acute respiratory distress induced by simple pulmonary factors. In addition, BNP and NT-proBNP are useful in the evaluation of disease severity and treatment guidance in children with pulmonary hypertension, cardiomyopathy and Kawasaki disease. Current limitations include the relatively small sample size of the study, the detection method and a range of normal values that are not completely uniform.
WANG Ye-Feng,HUANG Xi-Yong. Research advance of brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis and treatment of pediatric cardiovascular diseases[J]. CJCP, 2012, 14(06): 470-474.
[1]Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure[J]. Circulation, 2007, 116(5): e99-e109.
[3]Xu-Cai YO, Wu Q. Molecular forms of natriuretic peptides in heart failure and their implications[J]. Heart, 2010, 96(6): 419-424.
[4]Kuwahara K, Nakao K. Regulation and significance of atrial and brain natriuretic peptides as cardiac hormones[J]. Endocr J, 2010, 57(7), 555-565.
[5]Daniels LB, Allison MA, Clopton P, Redwine L, Siecke N, Taylor K, et al. Use of natriuretic peptides in preparticipation screening of college athletes[J]. Int J Cardiol, 2008, 124(3): 411-414.
[6]Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents[J]. Heart, 2003, 89(8): 875-878.
[7]Law YM, Hoyer AW, Reller MD, Silberbach M. Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children[J]. J Am Coll Cardiol, 2009, 54(15): 1467-1475.
[8]Sugimoto M, Manabe H, Nakau K, Furuya A, Okushima K, Fujiyasu H, et al. The role of N-terminal pro-B-type natriuretic peptide in the diagnosis of congestive heart failure in children[J]. Circ J, 2010, 74(5): 998-1005.
[10]Price JF, Thomas AK, Grenier M, Eidem BW, O'Brian Smith E, Denfield SW, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction[J]. Circulation, 2006, 114(10): 1063-1069.
[11]Mangat J, Carter C, Riley G, Foo Y, Burch M. The clinical utility of brain natriuretic peptide in paediatric left ventricular failure[J]. Eur J Heart Fail, 2009, 11(1): 48-52.
[12]Auerbach SR, Richmond ME, Lamour JM, Blume ED, Addonizio LJ, Shaddy RE, et al. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial[J]. Circ Heart Fail, 2010, 3(5): 606-611.
[13]Ariceta G, Brooks ER, Langman CB. Assessing cardiovascular risk in children with chronic kidney disease. B-type natriuretic peptide: a potential new marker[J]. Pediatr Nephrol, 2005, 20(12):1701-1707.
[14]Ouali S, Bougmiza I, Abroug S, Ormezzine A, Ben Salem H, Neffeti, et al. Relationship of brain natriuretic peptide concentrations to left ventricular function and adverse outcomes in children with end-stage renal disease undergoing hemodialysis[J]. Pediatr Cardiol, 2011, 32(5): 568-577.
[15]Cohen S, Springer C, Avital A, Perles Z, Rein AJ, Argaman Z, et al. Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress?[J]. Pediatrics, 2005, 115(5): 1347-1350.
[16]Koulouri S, Acherman RJ, Wong PC, Chan LS, Lewis AB. Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress[J]. Pediatr Cardiol, 2004, 25(4): 341-346.
[18]Bernus A, Wagner BD, Accurso F, Doran A, Kaess H, Ivy DD. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension[J]. Chest, 2009, 135(3): 745-751.
[19]Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension[J]. Int J Cardiol, 2009, 135(1): 21-26.
[20]Reynolds EW, Ellington JG, Vranicar M,Bada HS. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn[J]. Pediatrics, 2004, 114(5): 1297-1304.
[22]Mir TS, Falkenberg J, Friedrich B, Gottschalk U, Le TP, Laer S, et al. Levels of brain natriuretic peptide in children with right ventricular overload due to congenital cardiac disease[J]. Cardiol Young, 2005, 15(4): 396-401.
[23]Paul MA, Backer CL, Binns HJ, Mavroudis C, Webb CL, Yogev R, et al. B-Type natriuretic peptide and heart failure in patients with ventricular septal defect: a pilot study[J]. Pediatr Cardiol, 2009, 30(8): 1094-1097.
[24]Pietrzak R, Werner B. Usefulness of NT-proBNP in assessment of right ventricular function in children after tetralogy of Fallotcorrection-a preliminary study[J]. Kardiol Pol, 2009, 67(4): 378-383.
[25]Shah A, Feraco AM, Harmon C, Tacy T, Fineman JR, Bernstein HS. Usefulness of various plasma biomarkers for diagnosis of heart failure in children with single ventricle physiology[J]. Am J Cardiol, 2009, 104(9): 1280-1284.
[26]Kaski JP, Tomé-Esteban MT, Mead-Regan S, Pantazis A, Marek J, Deanfield JE, et al. B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy[J]. Heart, 2008, 94(10): 1307-1311.
[27]Rusconi PG, Ludwig DA, Ratnasamy C, Mas R, Harmon WG, Colan SD, et al. Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure[J]. Am Heart J, 2010, 160(4): 776-783.
[29]Babuin L, Alegria RJ, Oh JK, Nishimura RA, Jaffe AS. Brain natriuretic peptide levels in constrictive pericarditis and restrictive cardiomyopathy[J]. J Am Coll Cardiol, 2006, 47(7): 1489-1491.
[30]Takeuchi D, Saji T, Takatsuki S, Fujiwara M. Abnormal tissue doppler images are associated with elevated plasma brain natriuretic peptide and increased oxidativestress in acute Kawaski disease[J]. Circ J, 2007, 71(3): 357-362.
[31]Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint Cyr C, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of kawasaki disease[J]. Pediatr Cardiol, 2009, 30(6): 810-817.
[33]Jefferies JL, Denfield SW, Price JF, Dreyer WJ, McMahon CJ, Grenier MA, et al. A prospective evaluation of nesiritide in the treatment of pediatric heart failure[J]. Pediatr Cardiol, 2006, 27 (4): 402-407.
[34]Mahle WT, Cuadrado AR, Kirshbom PM, Kanter KR, Simsic JM. Nesiritide in infants and children with congestive heart failure[J]. Pediatr Crit Care Med, 2005, 6 (5): 543-546.